Table 1 Baseline and treatment characteristics
Overall | Methylprednisolone treated | No methylprednisolone | P value* | |
|---|---|---|---|---|
Number of patients | 114 | 52 | 62 | |
Age, years | 62 (54–72) | 60 (47–72) | 62 (56–72) | 0.166 |
No. of men/women | 77/37 | 35/17 | 42/20 | 0.961 |
No. of Caucasian/Non-Caucasian | 100/14 | 39/13 | 61/1 | < 0.001 |
No. of PR3 positive (%) | 65 (57.0) | 27 (51.9) | 38 (61.3) | 0.314 |
No. with pulmonary haemorrhage (%) | 26 (22.8) | 18 (34.6) | 8 (12.9) | 0.006 |
No. with other lung disease (%) | 59 (51.8) | 20 (38.5) | 39 (62.9) | 0.009 |
No. with ENT disease (%) | 49 (43.0) | 15 (28.8) | 34 (54.8) | 0.005 |
BVAS score | 18 (12–20) | 16 (12–22) | 20 (14–20) | 0.852 |
Glomeruli with crescents (%) | 60.0 (34.5–80) | 62.5 (33.0–77.0) | 58.5 (37.5–80.0) | 0.666 |
Baseline Creatinine, μmol/L | 619 (530–790) | 594 (506–787) | 647 (547–790) | 0.189 |
Plasma Exchange, No. of treatments | 7 (6–9) | 7 (5–7) | 7 (7–10) | < 0.001† |
MP dose, g | – | 1.5 (1.5–1.9) | – | – |
Total Cyclophosphamide dose, g | 7.2 (4.6–9.8) | 5.2 (3.6–9.4) | 8.6 (6.4–10.5) | 0.005 |
Total Oral Prednisolone dose (12 months), g | 5.5 (3.9–6.8) | 4.0 (3.9–5.3) | 6.8 (5.5–7.0) | < 0.001 |